Yuan Lei, Wang Jing, Ke Xiao-Yan
Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
Department of Hematology, Peking University Third Hospital, Beijing 100191, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Feb;29(1):288-292. doi: 10.19746/j.cnki.issn.1009-2137.2021.01.048.
T lymphoid malignancy is a group of highly heterogeneous hematological tumors. Disease recurrence and resistance to therapy are the common causes of failed treatment. Traditional therapy is radiotherapy and chemotherapy, although it has achieved great success. However, many patients still failed to survive following the treatment. With the introduction of monoclonal antibodies, immunotherapy and cellular therapy into clinical practice, the outcome of hematologic malignancies has been significantly improved. In particular, chimeric antigen receptor T cells (CAR-T) showed high efficacy in treating B-cell lymphoma and acute B lymphocytic leukemia and surpassed any previous therapeutic strategies. However, this treatment seldom succeeded in treating T cell malignancies. In this review, the history of CAR-T cells treating T cell malignancies, and the clinical trials, adverse events of previously reported were summarized briefly.
T淋巴细胞恶性肿瘤是一组高度异质性的血液肿瘤。疾病复发和对治疗的耐药性是治疗失败的常见原因。传统治疗方法是放疗和化疗，尽管已取得了巨大成功。然而，许多患者在治疗后仍未能存活。随着单克隆抗体、免疫疗法和细胞疗法引入临床实践，血液系统恶性肿瘤的治疗结果有了显著改善。特别是，嵌合抗原受体T细胞（CAR-T）在治疗B细胞淋巴瘤和急性B淋巴细胞白血病方面显示出高效性，超过了以往任何治疗策略。然而，这种治疗方法在治疗T细胞恶性肿瘤方面很少成功。在本综述中，简要总结了CAR-T细胞治疗T细胞恶性肿瘤的历史以及先前报道的临床试验和不良事件。
